Topol’s take on AI: Success and failure

Artificial intelligence shows great promise in recognizing patterns, liberating physicians from keyboards and predicting outcomes, but where does it fall short? Medical guru Eric Topol does a deep dive into those topics and many more in his new book, Deep Medicine.

Can AI help to reduce healthcare costs? Yes. Will AI replace physicians? No. “We can’t, and will never, rely on only algorithms for interpretation of life and death matters,” Topol said in an interview with The New York Times. “That requires human expert contextualization, something machines can’t do.”

And where does AI stand to falter? Beware of breaches in privacy and security, bias and ethical quandaries. But it goes far deeper.

Check out the interview here:

Mary Tierney
Mary C. Tierney, MS, Vice President & Chief Content Officer, TriMed Media Group

Mary joined TriMed Media in 2003. She was the founding editor and editorial director of Health Imaging, Cardiovascular Business, Molecular Imaging Insight and CMIO, now known as Clinical Innovation + Technology. Prior to TriMed, Mary was the editorial director of HealthTech Publishing Company, where she had worked since 1991. While there, she oversaw four magazines and related online media, and piloted the launch of two magazines and websites. Mary holds a master’s in journalism from Syracuse University. She lives in East Greenwich, R.I., and when not working, she is usually running around after her family, taking photos or cooking.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.